Introduction: The ideal response to HIV would be the discovery of an effective vaccine. Evaluation of the benefit/risk balance of this vaccine must include Africa, where the majority of HIV infections are observed. This study was designed to identify the perceptions and the medium-term acceptability of a potential vaccine trial in Ouagadougou (Burkina Faso).

Methods: After a "literature review", data were collected from key informants, "pimps" of prostitutes, representatives of HIV and/or AIDS associations, facilitators and peer educators. Data were transcribed and analysed manually.

Results: The vast majority of respondents considered that it would be relevant to test an HIV vaccine in Ouagadougou (Burkina Faso). Almost all prostitutes would participate in such a trial and would be motivated by several factors. Potential participants were willing to play the role expected of them. A real communication strategy will be needed to conduct this trial.

Discussion: The results of this study are similar to those of previous studies conducted in Burkina Faso concerning the acceptability/feasibility of clinical trials. Acceptability studies of clinical trials are therefore becoming less and less relevant. Reinforcing the skills/capacities of all stakeholders and/or adequate preparation of participants to play the role expected of them are therefore now more important than acceptability studies.

Download full-text PDF

Source

Publication Analysis

Top Keywords

clinical trials
12
burkina faso
12
hiv vaccine
8
ouagadougou burkina
8
participants play
8
play role
8
role expected
8
acceptability studies
8
hiv
5
vaccine
5

Similar Publications

Background: In severely injured trauma patients, hypofibrinoginaemia is associated with increased mortality. There is no evidence-based consensus for what constitutes optimal fibrinogen therapy, treatment dose or timing of administration. The aim of this systematic review was to evaluate the effects of early fibrinogen replacement, either cryoprecipitate or fibrinogen concentrate (FgC) on mortality, transfusion requirements and deep venous thrombosis (DVT).

View Article and Find Full Text PDF

Experiences, perceptions and ethical considerations of the malaria infection study in Thailand.

BMC Med Ethics

January 2025

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Thunphayathai, Bangkok, 10400, Thailand.

Background: Thailand has made significant progress in malaria control efforts in the past decade, with a decline in the number of reported cases. However, due to cross-border movements over the past 5 years, reported malaria cases in Thailand have risen. The Malaria Infection Study in Thailand (MIST) involves deliberate infection of healthy volunteers with Plasmodium vivax malaria parasites, and the assessment of the efficacy of potential vaccine and drug candidates in order to understand acquired protection against malaria parasites.

View Article and Find Full Text PDF

Background: Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the low to moderate quality of the generated evidence, safety concerns and restricted prescribing indications. Additional randomized trials are needed before this drug can be routinely integrated into cardio-oncology clinical practice.

View Article and Find Full Text PDF

Oxygen therapy is ubiquitous in critical illness but oxygenation targets to guide therapy remain controversial despite several large randomised controlled trials (RCTs). Findings from RCTs evaluating different approaches to oxygen therapy in critical illness present a confused picture for several reasons. Differences in both oxygen target measures (e.

View Article and Find Full Text PDF

Maturation inhibitors (MIs) block HIV-1 maturation by preventing the cleavage of the capsid protein and spacer peptide 1 (CA-SP1). Bevirimat (BVM), a first-in-class MI, displayed sub-optimal efficacy in clinical trials due to presence of SP1:V7A polymorphism in the Gag protein.This polymorphism is inherently present in HIV-1 subtype C and conferred resistance to BVM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!